Hi, I'm Nick.
A pharmacist
who builds things.

SoundSelf is one of the most genuinely novel tools in the mental health space — an immersive biofeedback system that uses voice, sound, light, and vibration to guide patients into deep meditative states, used alongside ketamine and Spravato as a preparation and integration tool. They also operate ketamine clinics directly, giving the technology a real-world clinical home.

The GTM challenge is not the technology. It is trust. Getting clinicians to change established patient care practices requires a specific kind of credibility — you have to speak their language, understand their workflow pressures, and make the case in clinical terms before commercial ones. I lead clinical business development for SoundSelf's market entry and ongoing expansion into the ketamine and Spravato clinic space: opening relationships, mapping clinic pain points, and creating the conditions for adoption in an industry where trust is the actual currency.

Embla is a Danish healthtech company doing something genuinely different in the GLP-1 space — behavior-first coaching paired with microdosed GLP-1s and structured tapering plans. They came to the US with $10M raised and a real problem: GLP-1s were on backorder, and American pharmaceutical procurement required a specialist.

I came in embedded with the founders and marketing team. We mapped the full procurement landscape — 340B, international sourcing, compounding, manufacturer direct, distributor partners, and payor channels — and made deliberate, defensible choices. By the end of the engagement, Embla had a durable procurement pathway built around compounding for defined medical necessity and a branded procurement strategy including international sourcing. I also identified claims in their marketing collateral that created regulatory exposure under FDA promotional guidelines — protecting the company before they became problems.

When I stepped away from Meeko, Revitalist reached out almost immediately — which is how these relationships tend to work when you've built a reputation in a small ecosystem.

I came in embedded with senior leadership at one of the more established multi-location ketamine clinic networks in the country — operationally active domestically and internationally, including patient care decisions reaching the British Virgin Islands. My scope covered clinical business development, service line expansion, marketing strategy, and the talent decisions that shape an organization's trajectory. The most valuable thing a fractional operator can do is compress decision-making cycles for senior leadership — showing up with enough context to give an honest read, fast.

Alyea is a pharmaceutical company developing Low Dose Naltrexone and a topical medication as non-addictive alternatives for Complex Regional Pain Syndrome and chronic pain, with FDA Orphan Drug Designation and late-stage clinical trials on the horizon. Their development pathway includes 505(b)(2) strategy, where real-world compounding data and clinical experience are directly relevant to regulatory submission.

What I brought was something most clinical trial teams don't have access to: hands-on compounding experience with the exact compounds in development. LDN and topical agents aren't theoretical to me, they're formulations I have worked with across hundreds to thousands of patients in clinical settings. That practitioner perspective materially changes how you think about formulation decisions, dosing rationale, and protocol design.

My scope included formulation input on a product in development, review of international clinical trial legal documents, and C-suite advisory through a period of organizational transition.

I work with companies whose mission I can stand behind. When that alignment shifts, I move on.

There is a version of this engagement that looks like advisory work. This is not that. I am embedded inside an early-stage telehealth company alongside medical leadership from Thirty Madison alumni, operating at the intersection of clinical, regulatory, and product in a way that most consultants cannot.

The scope spans clinical protocol development, state-by-state rollout strategy, DEA guidance and federal oversight navigation, pharmacy procurement partnerships, legal counsel relationships, and business infrastructure build.

On the clinical side specifically: I serve as Clinical Safety Advisor across pharmacy and regulatory landscape — building ketamine clinical safety architecture including titration protocols, dose ceilings, stopping rules, and lab strategy, alongside at-home care monitoring frameworks and standard-of-practice development.

On the product side: I work with the clinical team to translate medical and regulatory requirements into documentation the product team can actually build from. Bridging that translation gap is where most telehealth companies lose time and credibility. We close it early.

On the regulatory side: telehealth operates in a permanent negotiation between state licensing boards, federal DEA scheduling, and an evolving federal oversight framework that did not exist five years ago. Working alongside the team, we have mapped that architecture from the inside and built the compliance infrastructure to operate across it.

This is not an advisory role. I am part of the build.

Pearl Institute is a dual-structure psychedelic clinic and education organization in Western North Carolina — operating at the intersection of clinical care, research, community education, and policy. Serving in governance for an organization doing field-defining work in psychedelic-assisted care.